Changes of immunological parameters with administration of Japanese Kampo medicine (Juzen-Taihoto/TJ-48) in patients with advanced pancreatic cancer

International Journal of Clinical Oncology

Volumn 19, Issue 1, 2014, Pages 81-86

  Ikemoto, Tetsuya ^a   Shimada, Mitsuo ^a   Iwahashi, Shuichi ^a   Saito, Yu ^a   Kanamoto, Mami ^a   Mori, Hiroki ^a   Morine, Yuji ^a   Imura, Satoru ^a   Utsunomiya, Tohru ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Kampo medicine; Pancreatic cancer; Regulatory T cell; TJ 48; Tumor immunity

Indexed keywords

DRUGS, CHINESE HERBAL; HUMANS; KILLER CELLS, NATURAL; MEDICINE, KAMPO; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84894563665     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0529-6     Document Type: Article

References (31)

1. Hori S, Nomura T, Sakaguchi S, et al. (2003) Control of regulatory T cell development by the transcription factor Foxp3. Science 299:1057
2. Sakaguchi S, Sakaguchi N, Asano M, et al. (1995) Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 155:1151
3. + T-cell into hepatic parenchyma in mice. J Med Invest 51:178-185
4. Wood KJ, Sakaguchi S (2003) Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3(3):199-210
5. + T cells in peripheral blood in advanced pancreatic cancer. Pancreas 33(4):386-390
6. Bignone PA, Banham AH (2008) FOXP3(+) regulatory T cells as biomarkers in human malignancies. Expert Opin Biol Ther 8(12):1897-1920
7. O'Leary JG, Goodarzi M, Drayton DL, et al. (2006) T cell- and B cell-independent adaptive immunity mediated by natural killer cells. Nat Immunol 7(5):507-516
8. Dai Y, Kato M, Takeda K, et al. (2011) T-cell-immunity-based inhibitory effects of orally administrated herbal medicine Juzen-Taiho-to on the growth of primarily developed melanocytic tumor in RET-transgenic mice. J Invest Dermatol 117(3):694-701
9. Hosokawa Y (1986) Radioprotective effects of Chinese medical prescriptions in mice. J Tradit Med 3(3):164-169
10. Liu H, Wang J, Sekiyama A, et al. (2008) Juzen-Taiho-to, an herbal medicine, activates and enhances phagocytosis in microglia/macrophages. Tohoku J Exp Med 215(1):43-54
11. Fujiki K, Nakamura M, Matsuda T, et al. (2008) IL-12 and IL-18 induction and subsequent NKT activation effects of Japanese botanical medicine Juzen-taihoto. Int J Mol Sci 9(7):1142-1155
12. Syo Y, Fujisaki K, Sakashita H, et al. (2004) Orally administered Kampo medicine, Juzen-taiho-to, ameliorates anemia during interferon plus ribavirin therapy in patients with chronic hepatitis C. J Gastroenterol 39(12):1202-1204
13. Hisha H, Kohdera U, Hirayama M, et al. (2002) Treatment of Shwachman syndrome by Japanese herbal medicine (Juzen-taiho-to): stimulatory effects of its fatty acids on hemopoiesis in patients. Stem Cells 20(4):311-319
14. Sobin LH, Wittekind LH (2002) International Union Against Cancer (UICC). TNM classification of malignant tumors, 6th edn. Wiley-Liss, New York, pp 87-90
15. World Medical Association (1964) Declaration of Helsinki: ethical principles for medical research involving human subjects. In: 18th WMA General Assembly Helsinki, Finland
16. + regulatory T cells and plasma levels of soluble CD25. Tohoku J Exp Med 216(1):61-68
17. NCI Common Terminology Criteria for Adverse Events (CTCAE) v.4 data files. http://evs.nci.nih.gov/ftp1/CTCAE/About.html
18. Hiraya D, Kagohashi K, Satoh H (2010) Pneumonitis due to an herbal medicine, Otsu-ji-to. Eur J Intern Med 21(3):244
19. Makino T, Hishida A, Goda Y, et al. (2008) Comparison of the major flavonoid content of S. baicalensis, S. lateriflora, and their commercial products. J Nat Med 62(3):294-299
20. Ikegami F, Sumino M, Fujii Y, et al. (2006) Pharmacology and toxicology of Bupleurum root-containing Kampo medicines in clinical use. Hum Exp Toxicol 25(8):481-494
21. Morine Y, Shimada M, Ikegami T, et al. (2009) Usefulness of gemcitabine combined with 5-fluorouracil and cisplatin (GFP) in patients for unresectable biliary carcinoma. Hepatogastroenterology 56(90):307-312
22. Ferrone CR, Brennan MF, Gonen M, et al. (2008) Pancreatic adenocarcinoma: the actual 5-year survivors. J Gastrointest Surg 12(4):701-706
23. Tani M, Kawai M, Terasawa H, et al. (2007) Prognostic factors for long-term survival in patients with locally invasive pancreatic cancer. J Hepatobiliary Pancreat Surg 14(6):545-550
24. Bao PQ, Ramanathan RK, Krasinkas A, et al. (2011) Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol 18(4):1122-1129
25. Imamura M, Doi R, Imaizumi T, et al. (2004) A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery (St. Louis) 136(5):1003-1011
26. Takeda T, Yamaguchi T, Yaegashi N (2011) Perceptions and attitudes of Japanese gynecologic cancer patients to Kampo (Japanese herbal) medicines. Int J Clin Oncol 17(2):143-149
27. Lepisto AJ, Moser AJ, Zeh H, et al. (2008) A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther 6(B):955-964
28. Zhu Y, Tibensky I, Schmidt J, et al. (2008) Interferon-alpha enhances antitumor effect of chemotherapy in an orthotopic mouse model for pancreatic adenocarcinoma. J Immunother 31(7):599-606
29. + T cells in peripheral blood. Pancreas 42(1):130-134
30. Ikemoto T, Sugimoto K, Takita M, et al. (2011) Japanese herbal medicine TJ-48 prevents autoimmune diabetes in NOD mice. Am J Chin Med 39(4):743-756
31. Moretta A, Biassoni R, Bottino C, et al. (2000) Natural cytotoxicity receptors that trigger human NK-cell-mediated cytolysis. Immunol Today 21(5):228-234